



IZBrunch

Science meets Science

IN
COOPERATION
WITH



IZBrunch Investment Special

First Edition – “Go Big: How to win over US Investors”

Wednesday, October 2, 2024 | 9.45 a.m. to 12.30 p.m.

With our new event series “IZBrunch Investment Special,” we aim to spotlight the financing opportunities and strategies for biotech start-ups. The first session is dedicated to the key question: „How to win over US investors?“. What do start-ups need to do to attract US investors, and which factors should be considered when bringing them on board? These questions will be addressed by two experts who are well-connected in both the US and the DACH region: Charlie Cameron, an investment specialist and Dean Farmer, a leading patent strategist in the life sciences sector. Both are based in Boston and bring extensive insights from their years of experience.

Following their engaging presentations, a panel discussion will take place with Anne Burger, CFO of CatalYm, and Dominik Schumacher, CEO of Tubulis. Both companies recently closed successful funding rounds involving US investors.

Look forward to valuable insights and practical advice directly from the experts!

Your participation matters: What topics are you most interested in for this IZBrunch?
Feel free to submit your questions when registering, and we will forward them to the speakers.

Your hosts



Christian Gnam,
Managing Director, IZB



Dr. Christoph Eckert,
Project Manager, BioM

Location:

Faculty Club G2B on the 7th floor of the IZB Residence, Campus at Home Innovation and Start-up Center Biotechnology IZB
Am Klopferspitz 21
82152 Planegg/Martinsried

Format:

Face-to-face event with keynote presentations, a panel discussion with Q&A, followed by business lunch.

Participation requirements:

Admission is only possible after confirmed registration prior to the event. Please sign up at the Campus at Home reception at 9.45 am. The event starts at 10.00 am.

IMPORTANT NOTICE!

Registration/Contact:

To ensure an interactive event, the number of participants is limited to 50. We encourage early registration to secure your spot. As we are expecting a large number of signups, we kindly ask that you **limit attendance to one representative per company.**

Please register for the IZBrunch by September 24th by contacting us via email at koehler@izb-online.de

Marion Köhler
Head of Communications
Innovation and Start-up Center
Biotechnology (IZB)
Phone.: +49 (0)89 55 279 48-17
Mail: koehler@izb-online.de
www.izb-online.de



IZBrunch

Science meets Science

IN
COOPERATION
WITH



The speakers



Dean Famer

Dean is a leading patent strategist in the life sciences sector who works with biotechnology and pharmaceutical companies at all stages of development. His clients range from start-ups to mid-size pharmas with NCEs entering clinical trials, to large companies with vast patent portfolios. Dean's years working in the industry and two decades in patent law position him as a strategic partner for his clients. He helps them understand the risks and opportunities associated with various approaches to protect their innovations and helps them develop and implement strategies centered on their business goals.



Charles Cameron

Charlie is an expert in creating and connecting networks of venture capital funds in the US and Europe, with 17 years of experience in the DACH countries. He is the founder of Hub Angel Investment Fund, which is operating out of its seventh fund. Over the course of his career, he consulted with hundreds of entrepreneurs and founders worldwide on building and growing their businesses. As a global business development professional skilled in management strategy, marketing and capital raising, he has worked in over 40 countries in Europe, Asia, Africa and North America.



Anne Burger

Anne serves as Chief Financial Officer at CatalYm. She brings more than 15 years of experience in financial operations at biotech and medtech companies across Europe. Throughout her career, Anne has been responsible for corporate fundraising, executing trade sales and licensing agreements, and preparing for IPOs in several senior executive and advisory roles in the life sciences industry. As CFO of Rigontec, Anne played an active role in executing the sale of Rigontec to MSD (known as Merck & Co. in North America), a deal worth up to EUR 464 million.



Dominik Schumacher, PhD

Dominik serves as the Chief Executive Officer of Tubulis. Since its early founding phase, Dominik successfully secured several prestigious start-up awards for Tubulis. In 2019, he was awarded as one of MIT's Innovators Under 35. Dominik is also a Life Science Investor and has been actively investing in young, European biotech companies. Prior to co-founding Tubulis in 2018, Dominik worked at the Leibniz-Forschungsinstitut für Molekulare Pharmacology (FMP) and as a group leader at the Ludwig Maximilian University (LMU) in Munich.